abstract |
Provided are a peptides, nucleic acids encoding the same and host cells comprising a respective nucleic acid for use in the immunotherapy of cancer. Provided are also tumour-associated cytotoxic T cell (CTL) peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate antitumour immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. |